Chardan Rates Regeneron A Sell, Advises Caution
September 30, 2016 at 14:37 PM EDT
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) top line results from a mid-stage study of Eylea co-formulated with rinuccumab ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.